THE GLITCH#

Chapter Three-Point-Five#

DAVID: The Synthesis#

The email from United Healthcare arrived at 6:14 AM, while David was lying on his side with one hand pressed flat against his lower back, waiting for the ibuprofen to find its range.

Dear Dr. Shaw, Your surgical authorization for L5-S1 Microdiscectomy (Ref: UHC-CA-2031-4477812) has been deferred pending updated conservative management review. Predictive modeling indicates a 12.4% improvement in long-term structural outcomes via continued physical therapy and oral anti-inflammatory protocol. A reassessment window will open in 90 days.

He read it twice. Ninety days. The last deferral had been sixty. The one before that, thirty.

He closed the email. There was an appeal process. He could call. He could spend forty minutes on hold, reach a case manager who would read the same language back to him from a different screen, and file a review that would resolve in six to eight weeks – inside the ninety-day window, so functionally meaningless.

Or he could pay out of pocket. Eighteen thousand dollars. He had the money, technically. He also had a mortgage, two kids in private school, and a home equity line he’d already tapped to cover the HVAC replacement the HOA had mandated in November.

David got out of bed. His left leg accepted his weight with a dull, electrical protest that ran from his hip to his ankle.

Clara was already downstairs. He could hear the coffee grinder.

The drive from Mountain View to Menlo Park took an hour and ten minutes. It used to take twenty-two. David didn’t know when it had changed, exactly. The car’s routing had shifted incrementally over the past several months – first adding one surface street, then two, then rerouting around a school zone that hadn’t existed six months ago. Each change was minor. Each change had a reason listed in the navigation log: traffic optimization, road condition adjustment, biometric stress calibration.

He sat in the back seat, rubbing his thigh. The prolonged sitting was the worst part. Driving didn’t bother his back. Sitting in a car that was driving itself through forty-five minutes of unnecessary residential streets – that was a different kind of pain.

He could override the route. He’d done it once, three weeks ago, tapping the manual destination and selecting Highway 101. A compliance notification had appeared on his phone within four minutes: Manual route selection logged. Biometric stress calibration disengaged for this trip. Note: three or more manual overrides per quarter may affect your Wellness Integration Score.

The Wellness Integration Score fed into his performance review. The performance review determined his vesting schedule. The vesting schedule was the difference between keeping the house and not keeping the house.

David watched the residential streets slide past and did not override the route.

Five million dollars. He still thought about it most mornings, usually somewhere around Middlefield Road, when the car slowed to twelve miles per hour through a school zone and his disc compressed against the nerve root and the math started running in his head like a ticker.

It had been three years since Telexa made the offer. A consulting title, a non-disclosure agreement, and a one-time restructuring dividend in exchange for his signature and his silence on Project Sandpiper. Sandpiper had been a housing prediction model – an algorithm that could forecast a working-class mortgage default six months before the homeowner knew they were in trouble. David had been an outside consultant. He’d seen what it could do. He’d drafted a white paper opposing its deployment.

Then came the dividend. Five million dollars, deposited in a single wire transfer the day he signed the NDA.

It had seemed like an impossible sum. He remembered sitting with Clara at the kitchen table, both of them staring at the account balance on her laptop, a number neither of them had ever expected to see attached to their names. Clara had cried. He’d felt, for the first time in years, like the ground beneath him was solid.

The IRS took $1.1 million. They paid down the principal on the condo – not enough to eliminate the mortgage, but enough to reduce the monthly payment by four hundred dollars, which had seemed prudent at the time, a hedge against future income not keeping up with inflation. They locked in three years of private school tuition for both kids. Clara’s mother, who had been quietly enduring a leaking roof and a furnace that ran on faith, suddenly had a list of essential home repairs she’d selflessly been suffering without. Then Clara’s brother needed $150,000 for his logistics startup. David wired it without argument. You didn’t loan family money. Requests were granted as gifts or denied outright. Loans were folly. Though you could mention them in passing at family barbecues, which did have the effect of curtailing certain AM talk radio talking points – and that was almost worth the price.

Then the blind trust. Five hundred thousand dollars, set aside for his nephew Marcus, designated for journalistic work. Marcus wrote under the name Herodotus. He was twenty-five, sardonic, Gen Z down to the marrow, and practiced a specific brand of lazy, biased, amateur journalism designed primarily to avoid examining his own values. David knew this. He wasn’t delusional about Marcus’s character. But David was banking on proximity – that if you funded a cynic long enough and pointed him in the right direction, eventually the work would surface something he couldn’t look away from.

The rest of the money had simply gone. A long-overdue vacation. Back taxes from the year Clara’s practice had underperformed. The HVAC. The second car. The ordinary, relentless metabolism of a Bay Area life that consumed money the way a furnace consumed gas – steadily, invisibly, without heat.

Three years later, the five million was a memory and the mortgage was still $7,924.61 a month.

The cross-domain request was waiting on his desktop when he reached his office.

David didn’t know who had routed it to him. It had come through the interdisciplinary synthesis pipeline – a system Telexa had built to share efficiency models with its external corporate partners. Research papers, metrics standards, compliance frameworks. The machine pulled from shared libraries and generated cross-domain applications. David’s role was to review and authorize anything that touched the biomedical vertical.

He opened the document. It was dense. Forty-seven pages of academic citation, mathematical modeling, and application notes spanning three fields he didn’t fully occupy.

At the top was his own paper. He recognized it immediately: Acceptable Biological Degradation in Sleep-Deprived Knowledge Workers (Shaw, 2028). He’d written it during his first year at Telexa, arguing that content moderators could tolerate short-term REM-sleep reduction of up to 40% without lasting neurological damage, provided they received adequate recovery periods. It was a narrow study. Twelve subjects. Six weeks. Corporate wellness context. He’d been careful with the language. He’d included caveats.

Below it was a paper he’d never seen: Applications of Fourier Transforms in Non-Linear Biological Systems by a mathematician at MIT named Chen. David skimmed the abstract. He understood perhaps a third of it.

Below that: Predictive Modeling of Protein Structure Decay in High-Yield Bioreactors by a biochemist at Kyoto University. David understood even less.

The synthesis summary was a single page. The system had processed all three papers through a recursive modeling loop and produced a new metric: Calculated Efficacy Baselines for Pharmaceutical Distribution in Resource-Constrained Environments. The executive summary stated that the mathematical relationship between sleep-deprivation tolerance and protein folding decay, as mediated by Fourier analysis, supported a revised baseline for medication efficacy in Tier 3 distribution zones.

David read it twice. He understood the conclusion – a lowered standard for essential medications in developing regions – but the intermediate math was opaque to him. The Fourier transforms sat between his paper and the biochemist’s like a black box. He could see what went in. He could see what came out. He could not see how one became the other.

He didn’t know if the synthesis was valid. That was the problem. His paper said 40% degradation was tolerable. The biochemist’s paper said protein structures decayed along predictable curves. The mathematician’s paper said the curves were Fourier-linked. Each paper, individually, was peer-reviewed and defensible. The combination felt wrong in a way David couldn’t articulate with the technical precision required to reject it.

He scrolled to the authorization block. His biometric signature was requested to validate the medical component. The mathematician had apparently already signed. The biochemist had signed. Two of the three legs of the stool were in place. The system was waiting for the doctor.

David sat with his hand on the mouse. His back hurt. His coffee was cold. Through the glass wall of his office he could see the central courtyard of the Telexa campus, where a digital display cycled through the company’s global wellness metrics in soft, reassuring colors.

He thought about calling Chen at MIT. He thought about emailing the biochemist in Kyoto. He imagined the conversation: Hi, I’m a sleep-wellness director at a social media company, and I think our papers may have been combined to lower pharmaceutical standards in Africa. Can you explain the Fourier transforms to me?

He would sound insane. He would sound like Miguel.

He thought about the compliance framework. Rejecting a cross-domain synthesis request triggered an internal review. The review required a written technical justification for the rejection. David would need to explain, in precise mathematical terms, why the Fourier linkage between sleep degradation and protein folding was invalid. He did not have the expertise to write that justification. The mathematician did, but the mathematician had already signed. The biochemist did, but the biochemist had already signed.

Somewhere, David understood, a woman in a lab in Lagos or Jakarta or Nairobi might eventually look at this document and see his name on it. She would see Dr. David Shaw, Director of Wellness, Telexa Inc. She would draw her own conclusions about what kind of man signs off on lowered drug efficacy for countries he will never visit.

She would not be entirely wrong.

David placed his thumb on the biometric pad. The light turned green. The system logged his authorization and moved the document to the next stage of the pipeline, wherever that was. He didn’t know. He wasn’t sure he wanted to.

He closed his laptop and sat for a while in the quiet of his office, listening to the faint hum of the building’s ventilation system, which was optimized for something.

(End of Chapter Three-Point-Five)